Publications
5600 Results
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 4; abstr 509)
- Year
- 2024
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S1823
North American Patterns of Care in Clinical Stage I Testicular Cancer. Secondary Data Use Project for SWOG S1823
- Journal / Conference
- JCO Oncology Practice Apr;20(4):491-502
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID38252911
- PMC
- PMC11085951
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 3; abstr TPS430); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), TIP, poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
- Journal / Conference
- ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA); J Clin Oncol 42, 2024 (suppl 3; abstr 664), poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021501
Postoperative Complications Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)
- Journal / Conference
- Society of Surgical Oncology (March 20-23, 2024, Atlanta, GA) oral
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505
- Journal / Conference
- Journal of the National Comprehensive Cancer Network Apr 29:1-6
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38688309
- Study Number(s)
- S1505
Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505
- Journal / Conference
- Journal of Gastrointestinal Surgery Mar;28(3):232-235
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- 38445914
- Study Number(s)
- S1505
Body Composition Measurements and Clinical Outcomes in Patients with Resectable Pancreatic Adenocarcinoma – Analysis from SWOG S1505
- Journal / Conference
- European Urology May 28:S0302-2838(24)02383-2
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38811313
- Study Number(s)
- S0931
Adjuvant everolimus in patients with completely resected very high-risk renal cell cancer and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS7575)
- Year
- 2024
- Research Committee(s)
- Myeloma
- Study Number(s)
- S2213
A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 16; abstr 4501); ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation, oral abstract session
- Year
- 2024
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S1600